Cisplatin and etoposide in oesophageal cancer: a phase II study
| Autor: | H. W. Tilanus, H. Van Overhagen, T. C. Kok, G. Stoter, A. van der Gaast, Jan Dees, W. M. H. Eykenboom, Ted A.W. Splinter |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Cisplatin
Cancer Research Chemotherapy medicine.medical_specialty Dose business.industry medicine.medical_treatment Cancer Phases of clinical research medicine.disease Gastroenterology Surgery medicine.anatomical_structure Oncology Internal medicine Toxicity medicine Esophagus business Etoposide medicine.drug |
| Zdroj: | British Journal of Cancer. 74:980-984 |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.1996.469 |
| Popis: | In the search for effective chemotherapy regimens which can be used in multimodality treatment programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus. Seventy-three consecutive patients with unresectable or metastatic squamous cell carcinoma of the thoracic oesophagus were treated with cisplatin 80 mg m-2 by 4 h infusion on day 1, etoposide 100 mg (fixed dose) by 2 h infusion on day 1 and 2, and etoposide 200 mg m-2 orally on day 3 and 5. Courses were repeated every 4 weeks, for a maximum of six courses. The oral dosages of etoposide were modified individually until a significant degree of myelosuppression was reached. Of 65 evaluable patients, five complete responses (CRs) and 26 partial responses (PRs) were seen, for an overall response rate of 48% (95% confidence interval 35-60%). Median time to progression was 7 months (range 3-72 + months). There were two toxic deaths (neutropenic sepsis). The response rate equals that of other cisplatin-based regimens. Its toxicity profile allows addition of a third active drug such as 5-fluorouracil. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|